* severe covid-19 patients who met one of the following conditions: (1) respiratory rate (rr) ≥ 30 times / min; (2) sao2 / spo2 ≤ 93% in resting state; (3) arterial partial pressure of oxygen (pao2) / concentration of oxygen (fio2) ≤ 300 mmhg * critical covid-19 patients with one of the following conditions: (1) respiratory failure and need mechanical ventilation; (2) shock; (3) other organ failure combined with icu treatment; severe liver disease (such as child pugh score ≥ c, ast \> 5 times upper limit); * patients with contraindications specified for sofosbuvir- ledipasvir; the pregnancy test of female subjects during the screening period was positive, the researchers judged that the patient was not suitable to participate in this clinical study due to devastating co-morbid diseases (e.g. de-compensated liver disease, congested heart failure, chronic kidney disease, malignant or hematological disease under therapy or 3 months ago) and patients received antiviral eradication therapy for hepatitis c or b viruses within the previous 6 months. * patients with chloroquine contra-indications: qtc \> 500 m/sec, myasthenia gravis, porphyria, retinal pathology, epilepsy, g6pd deficiency, allergy to 4-aminoquinolone, chronic heart, kidney or liver disease, and arrhythmias. * any patient demonstrates worsening of symptoms, radiological progression with virologically persistence within at least 5 days of the therapeutic evaluation period of the study after exclusion of cytokine storm was considered as a clinical failure and was shifted to the other management protocol. * treatment was terminated at any time by a multidisciplinary team if a serious side effect occurred, which was attributed to the medications used ,e.g. cardiac arrhythmia, deteriorated liver or kidney function or unfortunately patient died .

* severe covid-19 patients who met one of the following conditions: (1) respiratory rate (rr) ≥ 30 times / min; (2) sao2 / spo2 ≤ 93% in resting state; (3) arterial partial pressure of oxygen (pao2) / concentration of oxygen (fio2) ≤ 300 mmhg * critical covid-19 patients with one of the following conditions: (1) respiratory failure and need mechanical ventilation; (2) shock; (3) other organ failure combined with icu treatment; severe liver disease (such as child pugh score ≥ c, ast \> 5 times upper limit); * patients with contraindications specified for sofosbuvir- ledipasvir; the pregnancy test of female subjects during the screening period was positive, the researchers judged that the patient was not suitable to participate in this clinical study due to devastating co-morbid diseases (e.g. de-compensated liver disease, congested heart failure, chronic kidney disease, malignant or hematological disease under therapy or 3 months ago) and patients received antiviral eradication therapy for hepatitis c or b viruses within the previous 6 months. * patients with chloroquine contra-indications: qtc \> 500 m/sec, myasthenia gravis, porphyria, retinal pathology, epilepsy, g6pd deficiency, allergy to 4-aminoquinolone, chronic heart, kidney or liver disease, and arrhythmias. * any patient demonstrates worsening of symptoms, radiological progression with virologically persistence within at least 5 days of the therapeutic evaluation period of the study after exclusion of cytokine storm was considered as a clinical failure and was shifted to the other management protocol. * treatment was terminated at any time by a multidisciplinary team if a serious side effect occurred, which was attributed to the medications used ,e.g. cardiac arrhythmia, deteriorated liver or kidney function or unfortunately patient died .

- severe covid-19 patients who met one of the following conditions: (1) respiratory rate (rr) ≥ 30 times / min; (2) sao2 / spo2 ≤ 93% in resting state; (3) arterial partial pressure of oxygen (pao2) / concentration of oxygen (fio2) ≤ 300 mmhg - critical covid-19 patients with one of the following conditions: (1) respiratory failure and need mechanical ventilation; (2) shock; (3) other organ failure combined with icu treatment; severe liver disease (such as child pugh score ≥ c, ast > 5 times upper limit); - patients with contraindications specified for sofosbuvir- ledipasvir; the pregnancy test of female subjects during the screening period was positive, the researchers judged that the patient was not suitable to participate in this clinical study due to devastating co-morbid diseases (e.g. de-compensated liver disease, congested heart failure, chronic kidney disease, malignant or hematological disease under therapy or 3 months ago) and patients received antiviral eradication therapy for hepatitis c or b viruses within the previous 6 months. - patients with chloroquine contra-indications: qtc > 500 m/sec, myasthenia gravis, porphyria, retinal pathology, epilepsy, g6pd deficiency, allergy to 4-aminoquinolone, chronic heart, kidney or liver disease, and arrhythmias. - any patient demonstrates worsening of symptoms, radiological progression with virologically persistence within at least 5 days of the therapeutic evaluation period of the study after exclusion of cytokine storm was considered as a clinical failure and was shifted to the other management protocol. - treatment was terminated at any time by a multidisciplinary team if a serious side effect occurred, which was attributed to the medications used ,e.g. cardiac arrhythmia, deteriorated liver or kidney function or unfortunately patient died .

- severe covid-19 patients who met one of the following conditions: (1) respiratory rate (rr) ≥ 30 times / min; (2) sao2 / spo2 ≤ 93% in resting state; (3) arterial partial pressure of oxygen (pao2) / concentration of oxygen (fio2) ≤ 300 mmhg - critical covid-19 patients with one of the following conditions: (1) respiratory failure and need mechanical ventilation; (2) shock; (3) other organ failure combined with icu treatment; severe liver disease (such as child pugh score ≥ c, ast > 5 times upper limit); - patients with contraindications specified for sofosbuvir- ledipasvir; the pregnancy test of female subjects during the screening period was positive, the researchers judged that the patient was not suitable to participate in this clinical study due to devastating co-morbid diseases (e.g. de-compensated liver disease, congested heart failure, chronic kidney disease, malignant or hematological disease under therapy or 3 months ago) and patients received antiviral eradication therapy for hepatitis c or b viruses within the previous 6 months. - patients with chloroquine contra-indications: qtc > 500 m/sec, myasthenia gravis, porphyria, retinal pathology, epilepsy, g6pd deficiency, allergy to 4-aminoquinolone, chronic heart, kidney or liver disease, and arrhythmias. - any patient demonstrates worsening of symptoms, radiological progression with virologically persistence within at least 5 days of the therapeutic evaluation period of the study after exclusion of cytokine storm was considered as a clinical failure and was shifted to the other management protocol. - treatment was terminated at any time by a multidisciplinary team if a serious side effect occurred, which was attributed to the medications used ,e.g. cardiac arrhythmia, deteriorated liver or kidney function or unfortunately patient died .